Journal Article

Isolated Presence of Antibody to Hepatitis B Core Antigen in Injection Drug Users: Do They Need to Be Vaccinated?

Gianluca Quaglio, Fabio Lugoboni, Sandro Vento, Alessandro Lechi, Augusto Accordini, Carlo Bossi, Marco Faccini, Valerio Mecenero, Alessandro Pani, Maurizio Pantalena, Margherita Residori and Paolo Mezzelani

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 32, issue 10, pages e143-e144
Published in print May 2001 | ISSN: 1058-4838
Published online May 2001 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/320162
Isolated Presence of Antibody to Hepatitis B Core Antigen in Injection Drug Users: Do They Need to Be Vaccinated?

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

In a study of 497 injection drug users who had isolated presence of antibody to hepatitis B core antigen (anti-HBc) at the time of enrollment, 404 (81%) retained this condition after a mean of 49 months of follow-up, during which time no new hepatitis B surface antigen marker was detected. These findings support the hypothesis that patients with isolated presence of anti-HBc have strong resistance to reinfection and do not need vaccination.

Journal Article.  1089 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.